October 24, 2011
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) clarified on October 21 the label changes for the type 2 diabetes treatment Actos (pioglitazone) and for pioglitazone-containing medicines from Takeda Pharmaceutical, and confirmed a...read more